The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma.
Smita SihagSamuel C NussenzweigHenry S WalchMeier HsuKay See TanSergio A De La TorreYelena Y JanjigianSteven B MaronGeoffrey Y KuLaura H TangPari M ShahAbraham Jing-Ching WuDavid R JonesDavid B SolitNikolaus SchultzKaruna GaneshMichael F BergerDaniela MolenaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
MDM2 amplification and TP53 status are associated with response to therapy in patients with esophageal adenocarcinoma. Given the dearth of actionable targets in esophageal adenocarcinoma, MDM2 inhibition, in combination with cytotoxic chemotherapy, may represent an important therapeutic strategy to overcome treatment resistance and improve outcomes in these patients.